Fifty years of paracetamol (acetaminophen) poisoning: the development of risk assessment and treatment 1973–2023 with particular focus on contributions published from Edinburgh and Denver
The DOI matches its Crossref record; 91 of the 91 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: Fifty years ago, basic scientific studies and the availability of assay methods made the assessment of risk in paracetamol (acetaminophen) poisoning possible. The use of the antidote acetylcysteine linked to new methods of risk assessment transformed the treatment of this poisoning. This review will describe the way in which risk assessment and treatments have developed over the last 50 years and highlight the remaining areas of uncertainty. METHODS: A search of PubMed and its subsidiary databases revealed 1,166 references published in the period 1963-2023 using the combined terms "paracetamol", "poisoning", and "acetylcysteine". Focused searches then identified 170 papers dealing with risk assessment of paracetamol poisoning, 141 with adverse reactions to acetylcysteine and 114 describing different acetylcysteine regimens. To manage the extensive literature, we focused mainly on contributions made by the authors during their time in Edinburgh and Denver. DOSE AND CONCENTRATION RESPONSE: The key relationship between paracetamol dose and toxicity risk was established in 1971 and led to the development of the Rumack-Matthew nomogram from data collected in Edinburgh. MECHANISMS OF TOXICITY: A series of papers on the mechanisms of toxicity were published in 1973, and these showed that paracetamol hepatotoxicity was caused by the formation of a toxic intermediate epoxide metabolite normally detoxified by glutathione but which, in excess, was bound covalently to hepatic enzymes and proteins. An understanding of the relationship between the rate of paracetamol metabolism, paracetamol concentration, and toxic hazard in humans soon followed. ANTIDOTE DEVELOPMENT AND EFFICACY IN PATIENTS: These discoveries were followed by the testing of a range of sulfhydryl-donors in animals and "at risk" patients. Acetylcysteine was developed as the lead intravenous antidote in the United Kingdom. The license holder in the United States refused to make an intravenous formulation. Thus, oral acetylcysteine became the antidote trialed in the United States National Multicenter Study. Intravenous acetylcysteine regimens used initially in the United Kingdom and subsequently in the United States used loading doses of 150 mg/kg over 15 minutes or one hour, 50 mg/kg over four hours, and 100 mg/kg over 16 hours. These regimens were associated with adverse drug reactions (nausea, vomiting and anaphylactoid reactions) and hence, treatment interruption. Newer dosing regimens now give loading doses more slowly. One, the Scottish and Newcastle Anti-emetic Pretreatment protocol, using an acetylcysteine regimen of 100 mg/kg over two hours followed by 200 mg/kg over 10 hours, has been widely adopted in the United Kingdom. A cohort comparison study suggests this regimen has comparable efficacy to standard regimens and offers opportunities for selective higher acetylcysteine dosing. RISK ASSESSMENT AT PRESENTATION: No dose-ranging studies with acetylcysteine were done, and no placebo-controlled studies were performed. Thus, there is uncertainty regarding the optimal dose of acetylcysteine, particularly in patients ingesting very large overdoses of paracetamol. The choice of intervention concentration on the Rumack-Matthew nomogram has important consequences for the proportion of patients treated. The United States National Multicenter Study used a "treatment" line starting at 150 mg/L (992 µmol/L) at 4 hours post overdose, extending to 24 hours with a half-life of 4 hours, now standard there, and subsequently adopted in Australia and New Zealand. In the United Kingdom, the treatment line was initially 200 mg/L (1,323 µmol/L) at 4 hours (the Rumack-Matthew "risk" line). In 2012, the United Kingdom Medicines and Healthcare products Regulatory Agency lowered the treatment line to 100 mg/L (662 µmol/L) at 4 hours for all patients, increasing the number of patients admitted and treated at a high cost. Risk assessment is a key issue for ongoing study, particularly following the development of potential new antidotes that may act in those at greatest risk. The development of biomarkers to assess risk is ongoing but has yet to reach clinical trials. CONCLUSION: Even after 50 years, there are still areas of uncertainty. These include appropriate acetylcysteine doses in patients who ingest different paracetamol doses or multiple (staggered) ingestions, early identification of at-risk patients, and optimal treatment of late presenters.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The history of paracetamol regulation therefore provides an instructive example of how evolving scientific evidence can influence both drug policy and clinical recommendations, albeit often with substantial delay relative to the accumulation of evidence [ 13 , 49 ].”
From Paracetamol: A History of Assumptions, Errors, and Evidence Reversals in Pain Management (2026) · cites this paper as [49]
Citations
Cites
ACETAMINOPHEN-INDUCED HEPATIC NECROSIS. IV. PROTECTIVE ROLE OF GLUTATHIONE
Mitchell, J. R., Jollow, D. J., Potter, W. Z., Gillette, J. R., & Brodie, B. B. (1973) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)29666-5 · Cited by 1,737
ACETAMINOPHEN-INDUCED HEPATIC NECROSIS. I. ROLE OF DRUG METABOLISM
Mitchell, J. R., Jollow, D. J., Potter, W. Z., Davis, D. C., Gillette, J. R., & Brodie, B. B. (1973) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)29663-x · Cited by 1,498 · cited 1×
“The scene was, therefore, set for a human antidote [12–14].”
BackgroundACETAMINOPHEN-INDUCED HEPATIC NECROSIS. II. ROLE OF COVALENT BINDING IN VIVO
Jollow, D. J., Mitchell, J. R., Potter, W. Z., Davis, D. C., Gillette, J. R., & Brodie, B. B. (1973) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)29664-1 · Cited by 1,204
Efficacy of Oral N-Acetylcysteine in the Treatment of Acetaminophen Overdose
Smilkstein, M. J., Knapp, G. L., Kulig, K. W., & Rumack, B. H. (1988) · New England Journal of Medicine · doi:10.1056/nejm198812153192401 · Cited by 1,102 · cited 4×
“The US National Multicenter Study, undertaken from 1976 to 1985, was published in 1988 [33].”
BackgroundMethodResultInfluentialSelf-citationParacetamol: New Vistas of an Old Drug
Bertolini, A., Ferrari, A., Ottani, A., Guerzoni, S., Tacchi, R., & Leone, S. (2006) · CNS Drug Reviews · doi:10.1111/j.1527-3458.2006.00250.x · Cited by 674
Intravenous N-acetylcystine: the treatment of choice for paracetamol poisoning.
Prescott, L. F., Illingworth, R. N., Critchley, J. A., Stewart, M. J., Adam, R. D., & Proudfoot, A. T. (1979) · BMJ · doi:10.1136/bmj.2.6198.1097 · Cited by 667 · cited 5×
“The US National Multicenter Study paper indicated that the 72 h oral acetyl-cysteine protocol had similar efficacy to the 20 h intravenous protocol [24,33].”
BackgroundMethodResultInfluentialSelf-citationAcetaminophen Poisoning and Toxicity
Rumack, B. H., & Matthew, H. (1975) · Pediatrics · doi:10.1542/peds.55.6.871 · Cited by 640
Self-citationPLASMA-PARACETAMOL HALF-LIFE AND HEPATIC NECROSIS IN PATIENTS WITH PARACETAMOL OVERDOSAGE
Prescott, L. F., Roscoe, P., Wright, N., & Brown, S. S. (1971) · The Lancet · doi:10.1016/s0140-6736(71)91125-1 · Cited by 611
Self-citationMitchell, J. R., Thorgeirsson, S. S., Potter, W. Z., Jollow, D. J., & Keiser, H. (1974) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt1974164676 · Cited by 532 · cited 4×
“These and subsequent experiments in animals suggested an optimal time window from exposure, and further detailed studies were conducted in the laboratories of the US manufacturer McNeil, which explored a wide range of potential sulfhydryl donors [14,15].”
BackgroundInfluentialAcute liver necrosis following overdose of paracetamol
Davidson, D. G., & Eastham, W. N. (1966) · BMJ · doi:10.1136/bmj.2.5512.497 · Cited by 528
Research works printed but not linked: 3
- 10.1001/archinte.1981.00340030118021 · doi:10.1001/archinte.1981.00340030118021
- Piperno E, Mosher AH, Berssenbrugge DA, et al. Pathophysiology of acetaminophen overdosage toxicity: implications for management. Pediatrics. 1978;62(5 Pt 2 Suppl):880–889.
- Waring WS, Pettie JM, Dow MA, et al. Paracetamol appears to protect against N-acetylcysteine-induced anaphylactoid reactions. Clin Toxicol. 2006;44:441–442.
Cited by
Ramachandran, A., Akakpo, J. Y., Curry, S. C., Rumack, B. H., & Jaeschke, H. (2024) · Biochemical Pharmacology · doi:10.1016/j.bcp.2024.116056 · Cited by 72
Self-citationLaser‐Induced Graphene Sensor for the Electrochemical Detection of Acetaminophen
Lahcen, A. A., Sher, M., Ameer, S., & Slaughter, G. E. (2025) · ChemistrySelect · doi:10.1002/slct.202502914 · Cited by 13
The multiple mechanisms and modes of cell death after acetaminophen overdose
Jaeschke, H., & Ramachandran, A. (2025) · Exploration of Digestive Diseases · doi:10.37349/edd.2025.100569 · Cited by 16
“One hypothesis that is sometimes brought up is that APAP-induced cell death might be caused by apoptosis, which rapidly deteriorates into secondary necrosis [11].”
Nakatsu, L., Lopez, J. R., Garcia, C. M., Cherian, M., Nash, J. L., Tofighi, D., Seifert, S. A., Smolinske, S. C., & Warrick, B. J. (2025) · Clinical Toxicology · doi:10.1080/15563650.2025.2456116 · Cited by 11
“…mainstay of treatment to prevent and treat hepatotoxicity for decades [2]. in 1977, Prescott et al. [3] proposed a three-bag intravenous 20.25 h regimen to treat paracetamol poisoning; this regimen was subsequently modified in 2011 in the United Kingdom (UK) to a three-bag regimen over 21 h [4,5].”
InfluentialWang, R., Chen, Y., Han, J., Ye, H., Yang, H., Li, Q., He, Y., Ma, B., Zhang, J., Ge, Y., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-55295-7 · Cited by 10
Metadata
- Authors
- Bateman, D. N., Dart, R. C., Dear, J. W., Prescott, L. F., & Rumack, B. H.
- Affiliations
- The Queen's Medical Research Institute (GB)
- Denver Health Medical Center (US)
- Corresponding author
- Bateman, D. Nicholas
- Venue
- Clinical Toxicology
- Publisher
- Informa UK Limited
- Published
- 2023-12-02
- Volume
- 61
- Issue
- 12
- Pages
- 1020-1031
- ISSN
- 0009-9309 (ISSN-L)
- 1556-3650
- 1556-9519
- OpenAlex
- W4390704606
- Cited by
- 25
- References
- 91
- Citations by year
- 2026: 4 · 2025: 15 · 2024: 6
- FWCI
- 1.71
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Toxicology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Emergency Medicine › Poisoning and overdose treatments
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Drug-Induced Hepatotoxicity and Protection
- Health Sciences › Medicine › Pathology and Forensic Medicine › Historical and Scientific Studies
- Keywords
- acetaminophen toxicity, paracetamol, N-acetylcysteine, Rumack-Matthew nomogram, dose-response relationship, glutathione, antidote efficacy, risk assessment, history of toxicology, hepatotoxicity
- MeSH terms
- Acetaminophen, Acetylcysteine, Antidotes, Antiemetics, Humans, Multicenter Studies as Topic, Risk Assessment, Analgesics, Non-Narcotic, Chemical and Drug Induced Liver Injury, Drug Overdose
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Fifty years of paracetamol (acetaminophen) poisoning: the development of risk assessment and treatment 1973–2023 with particular focus on contributions published from Edinburgh and Denver. https://app.cochat.ai/papers/10.1080/15563650.2023.2293452
- The paper
- Bateman, D. N., Dart, R. C., Dear, J. W., Prescott, L. F., & Rumack, B. H. (2023). Fifty years of paracetamol (acetaminophen) poisoning: the development of risk assessment and treatment 1973–2023 with particular focus on contributions published from Edinburgh and Denver. Clinical Toxicology. https://doi.org/10.1080/15563650.2023.2293452
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.